Tests a combination of drugs for children with relapsed B-cell acute lymphoblastic leukemia
Tests a multi-drug chemotherapy regimen in children with returning B-cell leukemia.
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Registry title
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 27 people, planned
- Started
- 14 Jul 2023
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cyclophosphamide
- Vincristine
- Blinatumomab
- Methotrexate
- Cytarabine
- Mercaptopurine
- Prednisone
- Pegfilgrastim
- Inotuzumab ozogamicin
- Rituximab
- Dexamethasone
- Record updated
- 23 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teens and young adults whose B-cell acute lymphocytic leukemia (B-ALL) has come back or did not respond to first treatment.
- Age
- From 1 year to under 25 years old.
- Sex
- All sexes can join.
- Disease stage
- B-ALL that has relapsed or is primary refractory. At least 5% leukemia cells (blasts) with CD19 and CD22 in the bone marrow, or in the blood if marrow cannot be taken. Leukemia in the brain or spine without symptoms is allowed.
- Earlier treatment
- Must be unable to receive anthracyclines or be intolerant to PEG-asparaginase. Must have recovered from earlier chemotherapy, surgery or radiation.
- Biomarker or test result
- Leukemia cells with CD19 and CD22. People without CD20 can join but will not receive rituximab.
Main reasons for not taking part
- Trisomy 21 or bone marrow failure syndromes
- Known active hepatitis B or C, or known HIV-positive
- Pregnant or breastfeeding
- Uncontrolled active infection
- Serious heart disease, liver cirrhosis, or active graft-versus-host disease needing treatment
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Pediatric, adolescent, or young adult patients with B-ALL as per NCCN v2.2021 and WHO classification in relapse or primary refractory and, either/both of the following: • Unable to receive anthracyclines (see section 3.1.8) or is PEG-asparaginase intolerant; For leukemia: Patients must have ≥ 5% blasts expressing CD19 and CD22 in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood; If patient does not have CD20, they can still be enrolled but will not receive rituximab
- Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥ 50% for patients who are > 16 years old
- Patients with asymptomatic CNS leukemia are eligible (see also Exclusion Criterion 3.2.2.)
- Age > = 1 years of age and less than 25 years of age
- The following baseline laboratory data:; Total serum bilirubin ≤1.5x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN; Adequate renal function per age51 unless related to the disease. Estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults); Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement
- Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and 30 days after the last treatment and 8 months after the last dose of inotuzumab and 12 months after the last dose of rituximab. Effective methods of birth control include:; Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin); Intrauterine devices (IUDs); Condom or occlusive cap (diaphragm or cervical/vault caps) used with Spermicide; Abstinence
- Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment and 5 months after the last dose of inotuzumab
- Patients with cardiac disease, include but not limited to: (Left ventricular ejection fraction (EF) < 50% (as determined by the Biplane Simpson method) (but not per exclusion criteria 3.2.3.1), or who have received >450mg/m2 of doxorubicin and cannot receive anthracyclines
Who cannot take part
- Past or current history of a secondary or other primary tumor or a chronic myeloid leukemia (CML) blast crisis with exception of:; Curatively treated non-melanomatous skin cancer; Other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years
- Patients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable
- Active acute/chronic Graft-versus-Host Disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy
- Prior history of allergic reaction to any of the agents
- Patients may be excluded if they are currently enrolled in another ongoing clinical trial with investigational products
- Presence of clinically significant uncontrolled CNS pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis. Presence of the following are allowed: headaches, vomiting, nerve palsy
- Medical history of cardiovascular disease such as:; ° Clinically significant cardiac disease including congestive heart failure (NYHA class III or IV) or arrhythmia or conduction abnormality requiring medication
- Known active hepatitis B or C infection or known seropositivity for HIV
- Patients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse
- Patients with Trisomy 21, or bone marrow failure syndromes are not eligible
- If patient has not recovered (as deemed by the investigator) from previous chemotherapy, surgery, radiation before the start of study drugs; ° To reduce the circulating blast count or palliation, the following are allowed prior to starting: Single dose intravenous cytarabine, steroids or hydroxyurea. No washout necessary for these agents
- Other severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated Protocol 2022-0312 V3 Dated 11/9/2023 Property of Leukemia at MD Anderson 17 with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study
- Females who are pregnant or lactating
- Male or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards
- Patients who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 25 years old?
Where in United States
- M D Anderson Cancer CenterHouston, United StatesContact: David McCall, MDTaking people
About the trial
What the trial wants to find out
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
The 2 groups in the trial
- Leukemia CNS1 or 2Treatment being tested
Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
Treatment: Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, and Dexamethasone
- Leukemia CNS 3Treatment being tested
Each study block, or cycle, is 28 days. Between every cycle below, Participants will have a 7-day rest period in which no study drug is given.
Treatment: Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, and Dexamethasone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- Plain-language title
- Tests a combination of drugs for children with relapsed B-cell acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05645718, who can take part
- Publications
- Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN, 2025
- Record updated
- 23 September 2026